Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline
Larissa A. Korde(National Cancer Institute), Dawn L. Hershman(Columbia University), Preeti Sudheendra(Cooper University Health Care), Elizabeth A. Morris(University of California Davis Medical Center), Rachel L. Yung(Seattle Cancer Care Alliance), Brittany Harvey(American Society of Clinical Oncology), Patricia A. Spears(University of North Carolina at Chapel Hill), Lisa A. Carey(University of North Carolina at Chapel Hill), Mark R. Somerfield(American Society of Clinical Oncology), Jennie R. Crews(CancerCare Manitoba), E. Shelley Hwang(Duke University), Seema A. Khan(Northwestern University), Sibylle Loibl(Goethe University Frankfurt), Neelima Denduluri(Washington Hospital), W. Fraser Symmans(The University of Texas MD Anderson Cancer Center), Alejandra Perez(University of Miami), Meredith M. Regan(Dana-Farber Cancer Institute)
Cited by 991
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
American Cancer Society Guidelines for Breast Screening with MRI as an Adjunct to Mammography
|CA A Cancer Journal for Clinicians|2007|2.6k
Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy
|Journal of Clinical Oncology|2007|1.6k
Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
|New England Journal of Medicine|2015|1.6k
The surgical destabilization of the medial meniscus (DMM) model of osteoarthritis in the 129/SvEv mouse
|Osteoarthritis and Cartilage|2007|1.5k